---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037936"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:39:40.520995+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q2 net loss $44.6M; axatilimab ORR up to 74% in cGVHD; two filings on track for 2023

## Summary
- Axatilimab AGAVE-201: ORR 74% at 0.3 mg/kg Q2W; all three cohorts met primary endpoint in cGVHD.
- Revumenib AUGMENT-101 topline data from KMT2Ar cohorts expected Q3 2023; NDA filing by year-end.
- Q2 2023 net loss $44.6M ($0.64/sh) vs $37.6M ($0.62/sh) in Q2 2022.
- Cash and investments $418.3M; 69.7M shares outstanding.
- FY 2023 R&D guidance $160-175M; total operating expenses $225-240M.

## SEC filing metadata
- accession: 0000950170-23-037936
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023037936/0000950170-23-037936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023037936/sndx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037936
- JSON: https://secwatch.observer/filing/0000950170-23-037936.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037936.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported the quarter ended June 30, 2023 results: net income net loss attributable to common stockholders of $44.6 million, or $0.64 per share, EPS $0.64 per share. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Net income: net loss attributable to common stockholders of $44.6 million, or $0.64 per share
  - EPS: $0.64 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: For the three months ended June 30, 2023, Syndax reported a net loss attributable to common stockholders of $44.6 million, or $0.64 per share, compared to a net loss attributable to common stockholders of $37.6 million, or $0.62 per share, for the comparable prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017023037936/0000950170-23-037936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.